Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
Cytokines and Cancer
share announcement

Cytokines and Cancer

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (31 October 2021) | Viewed by 12396

Special Issue Editor

Prof. Dr. Daniela Grimm

E-Mail Website
Guest Editor
1. Department of Microgravity and Translational Regenerative Medicine, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
2. Department of Biomedicine, Aarhus University, Aarhus, Denmark
Interests: space medicine; translational regenerative medicine; tissue engineering; cancer research; biomarker
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is characterized by an abnormal and malignant growth of cells. There are more than 100 types of cancer, and it is the second most common cause of death worldwide, with an estimated 18.1 million new cases of cancer (17 million excluding non-melanoma skin cancer) and 9.6 million deaths from cancer (9.5 million excluding non-melanoma skin cancer) worldwide in 2018 (WHO Global Cancer Observatory (GLOBOCAN) 2018). Tumor formation and progression is a multifactorial process, known to involve the dysregulation of cell growth, proliferation, and angiogenesis, each dependent on numerous different signaling pathways, with kinases playing a pivotal role.

Cytokines are increasingly secreted in response to inflammation, and they have been proposed to be involved in cancer development and progression. Cytokines act as messengers in the cross-talking between cancer cells and tumor-infiltrating immune cells. In addition, cancer cells can respond to host-derived cytokines that promote growth, attenuate apoptosis, and facilitate invasion and metastasis.

This Special Issue shall cover results of studies using animal or cell culture models to investigate the effects of cytokines in cancer, applying molecular biological, biochemical, and cell biological methods. This issue will also publish reports on patients, providing novel mechanistic insights of biomarkers in cancer. In addition, reviews on the current status of cancer biomarkers will be published.

Prof. Dr. Daniela Grimm
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cytokines
  • growth factors
  • cancer
  • biomarkers
  • metastasis
  • animal study
  • clinical study
  • cell cultures

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 1935 KiB  
Review
JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms
by Dania G. Torres, Jhemerson Paes, Allyson G. da Costa, Adriana Malheiro, George V. Silva, Lucivana P. de Souza Mourão and Andréa M. Tarragô
Biomolecules 2022, 12(2), 291; https://doi.org/10.3390/biom12020291 - 11 Feb 2022
Cited by 7 | Viewed by 4784
Abstract
The JAK2V617F variant constitutes a genetic alteration of higher frequency in BCR/ABL1 negative chronic myeloproliferative neoplasms, which is caused by a substitution of a G ˃ T at position 1849 and results in the substitution of valine with phenylalanine at codon 617 [...] Read more.
The JAK2V617F variant constitutes a genetic alteration of higher frequency in BCR/ABL1 negative chronic myeloproliferative neoplasms, which is caused by a substitution of a G ˃ T at position 1849 and results in the substitution of valine with phenylalanine at codon 617 of the polypeptide chain. Clinical, morphological and molecular genetic features define the diagnosis criteria of polycythemia vera, essential thrombocythemia and primary myelofibrosis. Currently, JAK2V617F is associated with clonal hematopoiesis, genomic instability, dysregulations in hemostasis and immune response. JAK2V617F clones induce an inflammatory immune response and lead to a process of immunothrombosis. Recent research has shown great interest in trying to understand the mechanisms associated with JAK2V617F signaling and activation of cellular and molecular responses that progressively contribute to the development of inflammatory and vascular conditions in association with chronic myeloproliferative neoplasms. Thus, the aim of this review is to describe the main genetic, hematological and immunological findings that are linked to JAK2 variant signaling in chronic myeloproliferative neoplasms. Full article
(This article belongs to the Special Issue Cytokines and Cancer)
►▼ Show Figures

Figure 1

16 pages, 3766 KiB  
Review
Update on Malignancy in Myositis—Well-Established Association with Unmet Needs
by Aleksandra H. Opinc and Joanna S. Makowska
Biomolecules 2022, 12(1), 111; https://doi.org/10.3390/biom12010111 - 11 Jan 2022
Cited by 10 | Viewed by 4266
Abstract
Idiopathic inflammatory myopathies are a group of rare connective tissue diseases with a well-documented association with malignancy. The mechanisms underlying the increased risk of neoplasms in the course of myositis are not fully understood. The Pubmed database has been thoroughly screened for articles [...] Read more.
Idiopathic inflammatory myopathies are a group of rare connective tissue diseases with a well-documented association with malignancy. The mechanisms underlying the increased risk of neoplasms in the course of myositis are not fully understood. The Pubmed database has been thoroughly screened for articles concerning cancer-associated myositis (CAM). The article summarizes the current state of knowledge on the epidemiology and pathogenesis of CAM. Furthermore, it analyses potential risk and protective factors for developing CAM, with particular emphasis on the association with distinct serological profiles. The review summarizes recommendations proposed so far for the management of CAM and presents a novel scheme for cancer screening proposed by the authors. Moreover, promising areas requiring further research were indicated. Full article
(This article belongs to the Special Issue Cytokines and Cancer)
►▼ Show Figures

Figure 1

21 pages, 1061 KiB  
Review
Functional Role of AKNA: A Scoping Review
by Abrahán Ramírez-González, Joaquín Manzo-Merino, Carla Olbia Contreras-Ochoa, Margarita Bahena-Román, José Manasés Aguilar-Villaseñor, Alfredo Lagunas-Martínez, Yvonne Rosenstein, Vicente Madrid Marina and Kirvis Torres-Poveda
Biomolecules 2021, 11(11), 1709; https://doi.org/10.3390/biom11111709 - 17 Nov 2021
Cited by 3 | Viewed by 2424
Abstract
Human akna encodes an AT-hook transcription factor whose expression participates in various cellular processes. We conducted a scoping review on the literature regarding the functional role of AKNA according to the evidence found in human and in vivo and in vitro models, stringently [...] Read more.
Human akna encodes an AT-hook transcription factor whose expression participates in various cellular processes. We conducted a scoping review on the literature regarding the functional role of AKNA according to the evidence found in human and in vivo and in vitro models, stringently following the “PRISMA-ScR” statement recommendations. Methods: We undertook an independent PubMed literature search using the following search terms, AKNA OR AKNA ADJ gene OR AKNA protein, human OR AKNA ADJ functions. Observational and experimental articles were considered. The selected studies were categorized using a pre-determined data extraction form. A narrative summary of the evidence was produced. Results: AKNA modulates the expression of CD40 and CD40L genes in immune system cells. It is a negative regulator of inflammatory processes as evidenced by knockout mouse models and observational studies for several autoimmune and inflammatory diseases. Furthermore, AKNA contributes to the de-regulation of the immune system in cancer, and it has been proposed as a susceptibility genetic factor and biomarker in CC, GC, and HNSCC. Finally, AKNA regulates neurogenesis by destabilizing the microtubules dynamics. Conclusion: Our results provide evidence for the role of AKNA in various cellular processes, including immune response, inflammation, development, cancer, autoimmunity, and neurogenesis. Full article
(This article belongs to the Special Issue Cytokines and Cancer)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop